These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25516553)

  • 21. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV.
    Shikuma CM; Nakamoto B; Shiramizu B; Liang CY; DeGruttola V; Bennett K; Paul R; Kallianpur K; Chow D; Gavegnano C; Hurwitz SJ; Schinazi RF; Valcour VG
    Antivir Ther; 2012; 17(7):1233-42. PubMed ID: 23018140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART.
    Castor D; Vlahov D; Hoover DR; Berkman A; Wu YF; Zeller B; Brechtl J; Hammer SM
    J Med Virol; 2009 Aug; 81(8):1323-35. PubMed ID: 19551816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
    Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
    Jevtović Dj; Vanovac V; Veselinović M; Salemović D; Ranin J; Stefanova E
    Biomed Pharmacother; 2009 Sep; 63(8):561-5. PubMed ID: 19026516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions.
    Caniglia EC; Cain LE; Justice A; Tate J; Logan R; Sabin C; Winston A; van Sighem A; Miro JM; Podzamczer D; Olson A; Arribas JR; Moreno S; Meyer L; del Romero J; Dabis F; Bucher HC; Wandeler G; Vourli G; Skoutelis A; Lanoy E; Gasnault J; Costagliola D; Hernán MA;
    Neurology; 2014 Jul; 83(2):134-41. PubMed ID: 24907236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan.
    Lai CC; Hung CC; Chen MY; Sun HY; Lu CL; Tseng YT; Chang SF; Su YC; Liu WC; Hsieh CY; Wu PY; Chang SY; Chang SC
    J Antimicrob Chemother; 2012 May; 67(5):1254-60. PubMed ID: 22302562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems.
    De Luca A; Cozzi-Lepri A; Perno CF; Balotta C; Di Giambenedetto S; Poggio A; Pagano G; Tositti G; Piscopo R; Del Forno A; Chiodo F; Magnani G; d'Arminio Monforte A; ;
    Antivir Ther; 2004 Oct; 9(5):743-52. PubMed ID: 15535412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Central nervous system penetration-effectiveness rank does not reliably predict neurocognitive impairment in HIV-infected individuals.
    Libertone R; Lorenzini P; Balestra P; Pinnetti C; Ricottini M; Plazzi MM; Menichetti S; Zaccarelli M; Nicastri E; Bellagamba R; Ammassari A; Antinori A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19655. PubMed ID: 25394159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.
    Marra CM; Zhao Y; Clifford DB; Letendre S; Evans S; Henry K; Ellis RJ; Rodriguez B; Coombs RW; Schifitto G; McArthur JC; Robertson K;
    AIDS; 2009 Jul; 23(11):1359-66. PubMed ID: 19424052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time.
    Frentz D; Boucher CA; Assel M; De Luca A; Fabbiani M; Incardona F; Libin P; Manca N; Müller V; O Nualláin B; Paredes R; Prosperi M; Quiros-Roldan E; Ruiz L; Sloot PM; Torti C; Vandamme AM; Van Laethem K; Zazzi M; van de Vijver DA
    PLoS One; 2010 Jul; 5(7):e11505. PubMed ID: 20634893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV Antiretroviral Medication Neuropenetrance and Neurocognitive Outcomes in HIV+ Adults: A Review of the Literature Examining the Central Nervous System Penetration Effectiveness Score.
    Arentoft A; Troxell K; Alvarez K; Aghvinian M; Rivera Mindt M; Cherner M; Van Dyk K; Razani J; Roxas M; Gavilanes M
    Viruses; 2022 May; 14(6):. PubMed ID: 35746623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High rates of baseline antiretroviral resistance among HIV-infected pregnant women in an HIV referral centre in Rio de Janeiro, Brazil.
    de Lourdes Teixeira M; Nafea S; Yeganeh N; Santos E; Gouvea MI; Joao E; Ceci L; Bressan C; Cruz ML; Sidi LC; Nielsen-Saines K
    Int J STD AIDS; 2015 Nov; 26(13):922-8. PubMed ID: 25504831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
    Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
    Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: do protease inhibitors improve survival regardless of central nervous system penetration-effectiveness (CPE) score?
    Fanjul F; Riveiro-Barciela M; Gonzalez J; Delgado E; Murillas J; Payeras Cifré A; Falcó V; Riera M
    HIV Med; 2013 May; 14(5):321-5. PubMed ID: 23217049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment initiation factors and cognitive outcome in youth with perinatally acquired HIV infection.
    Lazarus JR; Rutstein RM; Lowenthal ED
    HIV Med; 2015 Jul; 16(6):355-61. PubMed ID: 25604610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
    J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of High-Dose Multi-Strain Probiotic Supplementation on Neurocognitive Performance and Central Nervous System Immune Activation of HIV-1 Infected Individuals.
    Ceccarelli G; Brenchley JM; Cavallari EN; Scheri GC; Fratino M; Pinacchio C; Schietroma I; Fard SN; Scagnolari C; Mezzaroma I; Vullo V; d'Ettorre G
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29160817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.